AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26443655 — intervention group
Group type: COMPARATOR
Intervention: Off-site simulation (OSS)
Number of subjects: 25
Study 23561330 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose β‐conglycinin (2.3 g/d)
Number of subjects: 100
Study 23561330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose β‐conglycinin (4.6 g/d)
Number of subjects: 100
Study 23561330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four casein tablets/d)
Number of subjects: 100
Study 22717090 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone with light therapy
Number of subjects: 36
Study 22717090 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 36
Study 20643172 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment through a modified curriculum for EFNEP, with participants receiving a goal sheet after each of 6 classes.
Number of subjects: 54
Study 20643172 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment related to fiber, vegetable, and water consumption goals.
Number of subjects: 54
Study 18235414 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenesis treatment (humanized monoclonal antibody targeting vascular endothelial growth factor)
Number of subjects: 0
Study 18235414 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-angiogenesis treatment (low-molecular-weight anti tyrosine kinases)
Number of subjects: 0
Study 18235414 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 15204276 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Cruise Control (ACC)
Number of subjects: 0
Study 15204276 — intervention group
Group type: COMPARATOR
Intervention: Manual Driving
Number of subjects: 0
Study 11136285 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid alone (10 mg.day/kg)
Number of subjects: 154
Study 11136285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (chenodeoxycholic acid plus ursodeoxycholic acid, 5 mg.day/kg each)
Number of subjects: 154
Study 9700583 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1,600 mg/day for one year
Number of subjects: 66
Study 9700583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9700583 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 66
Study 7850850 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 quick rinses with 10 ml of water (experiment A)
Number of subjects: 8
Study 7850850 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 long-lasting rinse with 5 ml of water (experiment B)
Number of subjects: 8
Study 7850850 — intervention group
Group type: EXPERIMENTAL
Intervention: No water rinse after toothbrushing (experiment C)
Number of subjects: 8
Study 7850850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of toothpaste slurry with 100 ml of de-ionized water (experiment D)
Number of subjects: 8
Study 3139730 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg/day
Number of subjects: 60
Study 3139730 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 60
Study 28249384 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound exercise (30 minutes, three times per week for 12 weeks)
Number of subjects: 60
Study 28249384 — intervention group
Group type: COMPARATOR
Intervention: Control group (reading health magazines or watching television)
Number of subjects: 60
Study 27236732 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative treatment (surgery, radiosurgery, or embolization)
Number of subjects: 540
Study 27236732 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization prior to surgery or radiosurgery
Number of subjects: 540
Study 27236732 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 540
Study 24736200 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D [25(OH)D] levels
Number of subjects: 530
Study 23544333 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (1 mg x kg(‐1), 50 mg max) administered before surgery in group F (n = 11)
Number of subjects: 24
Study 23544333 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n = 13) with no flurbiprofen administration
Number of subjects: 24
Study 20723545 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs) for patients with early-onset anemia (≤ 8 weeks of treatment)
Number of subjects: 3023
Study 20723545 — intervention group
Group type: COMPARATOR
Intervention: No ESA use in patients with early-onset anemia
Number of subjects: 3023
Study 20723545 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs) for patients with late-stage anemia
Number of subjects: 3023
Study 20723545 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of Hb decrease (>3 g/dL)
Number of subjects: 3023
Study 20723545 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of Hb decrease (≤3 g/dL)
Number of subjects: 3023
Study 18221349 — intervention group
Group type: EXPERIMENTAL
Intervention: Child sexual abuse
Number of subjects: 158
Study 18221349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 158
Study 18221349 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile onset major depression
Number of subjects: 158
Study 18221349 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic major depressive disorder
Number of subjects: 158
Study 18221349 — intervention group
Group type: EXPERIMENTAL
Intervention: High adversity
Number of subjects: 158
Study 16190095 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ)
Number of subjects: 30
Study 16190095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12720050 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone 4 (MK(4)) at a dose of 45 mg/day for 2 weeks
Number of subjects: 20
Study 12720050 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone for 2 weeks (Control)
Number of subjects: 20
Study 10321403 — intervention group
Group type: EXPERIMENTAL
Intervention: READER method
Number of subjects: 92
Study 10321403 — intervention group
Group type: COMPARATOR
Intervention: Free appraisal
Number of subjects: 92
Study 8912486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 8912486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 449
Study 8912486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg)
Number of subjects: 449
Study 8912486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (20 mg)
Number of subjects: 449
Study 8912486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (40 mg)
Number of subjects: 449
Study 1365485 — intervention group
Group type: EXPERIMENTAL
Intervention: droxicam (20mg/day)
Number of subjects: 20
Study 1365485 — intervention group
Group type: COMPARATOR
Intervention: indomethacin (100mg/day)
Number of subjects: 20
Study 6351216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1 g)
Number of subjects: 604
Study 6351216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole (ASA + D)
Number of subjects: 604
Study 6351216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 604
Study 6351216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 604
Study 6351216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Dipyridamole (AD)
Number of subjects: 604
Study 6351216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) and Aspirin + Dipyridamole (AD)
Number of subjects: 604
Study 29926432 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching the film
Number of subjects: 81
Study 29926432 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 81
Study 30091979 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 150
Study 30091979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 27100375 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention including a personalized weight graph, education on recommended weight gain, prescription of exercise, and monitoring of weight until 1 year after delivery
Number of subjects: 445
Study 27100375 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 445
Study 27100375 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 445
Study 27100375 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain above Institute of Medicine recommendations
Number of subjects: 445
Study 25139698 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk-to-head bathing
Number of subjects: 62
Study 25139698 — intervention group
Group type: COMPARATOR
Intervention: Head-to-trunk bathing (Control)
Number of subjects: 62
Study 22275142 — intervention group
Group type: EXPERIMENTAL
Intervention: Esreboxetine 4 mg/day
Number of subjects: 1122
Study 22275142 — intervention group
Group type: EXPERIMENTAL
Intervention: Esreboxetine 8 mg/day
Number of subjects: 1122
Study 22275142 — intervention group
Group type: EXPERIMENTAL
Intervention: Esreboxetine 10 mg/day
Number of subjects: 1122
Study 22275142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1122
Study 20619634 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy with sequential chemotherapy
Number of subjects: 540
Study 20619634 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy alone
Number of subjects: 540
Study 18156031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alfa-2a (10 mg/kg every 2 weeks; 9 MIU subcutaneously three times weekly)
Number of subjects: 649
Study 18156031 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus interferon alfa-2a (9 MIU subcutaneously three times weekly)
Number of subjects: 649
Study 18156031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus interferon alfa-2a
Number of subjects: 649
Study 18156031 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus interferon alfa-2a
Number of subjects: 649
Study 15153904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1% applied twice daily
Number of subjects: 1
Study 15153904 — intervention group
Group type: COMPARATOR
Intervention: Inactive vehicle applied twice daily
Number of subjects: 1
Study 15153904 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing with tacrolimus 2.5% in ethanol
Number of subjects: 1
Study 11240334 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal feeding (JF)
Number of subjects: 60
Study 11240334 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 9519948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg twice daily for 6 months
Number of subjects: 281
Study 9519948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 9519948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 281
Study 7595697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HD-CNV) with cyclophosphamide 2.4 g/m2, mitoxantrone 35 to 45 mg/m2, and etoposide (VP16) 2.5 g/m2
Number of subjects: 90
Study 7595697 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CNV) with cyclophosphamide 600 mg/m2, mitoxantrone 12 mg/m2, and vincristine 1.4 mg/m2
Number of subjects: 90
Study 2625542 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 dB white noise with varying illumination levels (50, 150, 300 lx)
Number of subjects: 12
Study 2625542 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 dB white noise with varying illumination levels (50, 150, 300 lx)
Number of subjects: 12
Study 2625542 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 dB white noise
Number of subjects: 12
Study 2625542 — intervention group
Group type: EXPERIMENTAL
Intervention: Illumination levels (50, 150, 300 lx)
Number of subjects: 12
Study 1108600 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine anti-human-lymphocyte globulin (ALG)
Number of subjects: 31
Study 1108600 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 31922899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure (CPAP) for 3 months
Number of subjects: 53
Study 31922899 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure (CPAP) for 3 months
Number of subjects: 53
Study 31922899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 53
Study 29762517 — intervention group
Group type: EXPERIMENTAL
Intervention: Legislation to restrict HFSS TV advertising until 9:30 pm
Number of subjects: 0
Study 27392007 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention designed to enhance resilience and communication in families affected by caregiver HIV.
Number of subjects: 0
Study 27392007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study 24232192 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical activity plus behavioral counseling (SPA + BC group)
Number of subjects: 32
Study 24232192 — intervention group
Group type: COMPARATOR
Intervention: Supervised physical activity plus standard exercise counseling (SPA + EC group)
Number of subjects: 32
Study 23593156 — intervention group
Group type: EXPERIMENTAL
Intervention: New occlusal adjustment therapy
Number of subjects: 21
Study 19229275 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus nepafenac for 1 month
Number of subjects: 79
Study 19229275 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (topical antibiotic for 10 days and topical corticosteroid for 1 month)
Number of subjects: 79
Study 18709032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg epidural butorphanol with bupivacaine
Number of subjects: 120
Study 18709032 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg epidural butorphanol with bupivacaine
Number of subjects: 120
Study 18709032 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine alone
Number of subjects: 120
Study 15341548 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise and coping classes (6 months, 3 meetings weekly, 45 minutes each for exercise and 2 meetings weekly, 45 minutes each for coping)
Number of subjects: 185
Study 15341548 — intervention group
Group type: COMPARATOR
Intervention: Health education control intervention (6 months, 1 meeting weekly, 45 minutes)
Number of subjects: 185
Study 11080603 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational program (2-day duration)
Number of subjects: 30
Study 11080603 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 30
Study 9828976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: HIV preventive programme
Number of subjects: 1004
Study 7569150 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined therapy (CCT) with 2 mg estradiol valerate and 2.5 mg medroxyprogesterone acetate
Number of subjects: 50
Study 7569150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release theophylline tablets
Number of subjects: 24
Study 2804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release theophylline granules
Number of subjects: 24
Study 2804252 — intervention group
Group type: COMPARATOR
Intervention: Institutionalized group
Number of subjects: 24
Study 2804252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 1211536 — intervention group
Group type: EXPERIMENTAL
Intervention: Heineke-Mikulicz pyloroplasty
Number of subjects: 200
Study 1211536 — intervention group
Group type: COMPARATOR
Intervention: Finney pyloroplasty
Number of subjects: 200
Study 31900673 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS InLine veneers with thickness L1 (0.2-0.5 mm)
Number of subjects: 80
Study 31900673 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS InLine veneers with thickness L2 (0.5-1.2 mm)
Number of subjects: 80
Study 31900673 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including various preparation designs)
Number of subjects: 80
Study 31900673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin veneers and preparations with medium to high dentin portions
Number of subjects: 80
Study 31900673 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting resin composite restorations
Number of subjects: 80
Study 31018565 — intervention group
Group type: EXPERIMENTAL
Intervention: EATS (Eating Advice to Students) web-based nutrition intervention
Number of subjects: 124
Study 31018565 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 124
Study 28649001 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and Carboplatin (VC)
Number of subjects: 497
Study 28649001 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Carboplatin, and Etoposide (VCE)
Number of subjects: 497
Study 26198394 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (VLNC) at 0.5 mg/cigarette for 7 months followed by 12 months with no intervention
Number of subjects: 135
Study 26198394 — intervention group
Group type: COMPARATOR
Intervention: Usual brand of cigarettes
Number of subjects: 135
Study 23538479 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet or anticoagulant therapy
Number of subjects: 104
Study 23538479 — intervention group
Group type: COMPARATOR
Intervention: No antiplatelet or anticoagulant therapy
Number of subjects: 104
Study 20226548 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG250: 250 μg/kg bolus, 15 μg/kg/min infusion)
Number of subjects: 138
Study 20226548 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG300: 300 μg/kg bolus, 20 μg/kg/min infusion)
Number of subjects: 138
Study 20226548 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG350: 350 μg/kg bolus, 25 μg/kg/min infusion)
Number of subjects: 138
Study 20226548 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH: 70-100 IU/kg bolus)
Number of subjects: 138
Study 20226548 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (all doses)
Number of subjects: 138
Study 20226548 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG250: 2.8%, ARG300: 0.0%, ARG350: 3.2%)
Number of subjects: 138
Study 20226548 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 138
Study 19692798 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 70 mg
Number of subjects: 300
Study 19692798 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 50 mg
Number of subjects: 300
Study 19692798 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 25 mg
Number of subjects: 300
Study 19692798 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 10 mg
Number of subjects: 300
Study 19692798 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg
Number of subjects: 300
Study 19692798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 16721551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceram.X/K‐0127
Number of subjects: 43
Study 16721551 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram/Syntac Classic
Number of subjects: 43
Study 15249520 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication training
Number of subjects: 747
Study 15249520 — intervention group
Group type: EXPERIMENTAL
Intervention: SDM skill development
Number of subjects: 747
Study 15249520 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication aids followed by SDM skill development
Number of subjects: 747
Study 15249520 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication tools
Number of subjects: 747
Study 11751349 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, retroactive intercessory prayer
Number of subjects: 3393
Study 11751349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prayer)
Number of subjects: 3393
Study 9425968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine (100 microg)
Number of subjects: 100
Study 9425968 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 100
Study 9425968 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.5 mg)
Number of subjects: 100
Study 9425968 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100
Study 9425968 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2-4 mg/kg/h)
Number of subjects: 100
Study 8248762 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) measured with a handheld electronic pressure algometer (Somedic®)
Number of subjects: 12
Study 3307727 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine by intermittent intravenous injection
Number of subjects: 13
Study 3307727 — intervention group
Group type: COMPARATOR
Intervention: Morphine by continuous intravenous infusion
Number of subjects: 13
Study 30593142 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES therapy
Number of subjects: 82
Study 30593142 — intervention group
Group type: COMPARATOR
Intervention: Sham NMES
Number of subjects: 82
Study 27260592 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulation therapy (40 intensive sessions over 10 weeks)
Number of subjects: 5
Study 27260592 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulation therapy
Number of subjects: 5
Study 25002136 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus (500 mg)
Number of subjects: 8
Study 25002136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 22474864 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 22474864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21087898 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily for 5 years)
Number of subjects: 6241
Study 18281670 — intervention group
Group type: EXPERIMENTAL
Intervention: vitespen (autologous, tumor-derived heat shock protein gp96 peptide complexes)
Number of subjects: 322